Loading organizations...
LivaNova is a medical technology company delivering innovative patient solutions. It specializes in advanced therapies and devices for cardiopulmonary support, drug-resistant epilepsy, and difficult-to-treat depression. Its technical approach leverages decades of experience, utilizing VNS Therapy™ and proven cardiopulmonary innovations to enhance patient care.
Formed in 1987, headquartered in London, LivaNova built its foundation on a rich history of medical device expertise. The company represents accumulated technological advancements and collective experience within the medtech sector. This entity leads, committed to advancing patient well-being through specialized solutions, not from a singular founding event.
LivaNova’s products serve patients, healthcare professionals, and healthcare systems worldwide. Its mission extends beyond treating conditions, aspiring to fundamentally alter life trajectories through medical advancements. The company maintains a forward-looking vision, continually developing transformative technologies for critical unmet needs in global healthcare.
Key people at LivaNova.
LivaNova has 3 tracked investments across 3 companies. The latest tracked deal is $26.0M Series B in Cadence Neuroscience in May 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 17, 2023 | Cadence Neuroscience | $26.0M Series B | Gerry Brunk | Paolo DI Giorgio, Kevin CHU, JAZZ Venture Partners, Mayo Clinic, Spectrum Financial Services |
| Sep 25, 2018 | Ceribell | $35.0M Series B | Yongzhi Jiang | UCB Ventures |
| Oct 1, 2017 | HighLife | $14.0M Series A | Soffinova Partners | — |
